论文部分内容阅读
非甲、非乙型肝炎是引起急、慢性肝病常见而重要的原因,散发性肝炎中的20%～40%和输血后肝炎中的90%以上是由非甲、非乙型肝炎病毒所引起的。研究已证明,慢性活动性非甲,非乙型肝炎中有半数患者,在用重组人α-干扰素(α-IFN)治疗期间(每天200万U,每周3次,16周),血清转氨酶迅速降低,最终降至正常或接近正常,而停止治疗后,多数患者的转氨酶又迅速回升至治疗前水平。为了找出IFN治疗的最佳剂量,作者采用2倍剂量α-IFN(400万U,每周3次,16周)进行了研究。
Non-A, non-B hepatitis is a common and important cause of acute and chronic liver disease, 20% to 40% of sporadic hepatitis and more than 90% of post-transfusion hepatitis are caused by non-A, non-B hepatitis virus of. Studies have shown that half of patients with chronic active non-A, non-B hepatitis develop serum levels of IFN-γ during treatment with recombinant human interferon alpha (2 million U per day for three weeks, 16 weeks) Aminotransferase rapidly decreased eventually to normal or near normal, and stop treatment, the majority of patients and transaminases rapidly rose to pre-treatment levels. To find the optimal dose of IFN therapy, the authors studied with 2-fold dose of α-IFN (4 million U, 3 times a week, 16 weeks).